Somnair develops novel treatments for obstructive sleep apnea with its first-in-class non-invasive neurostimulation oral appliance, a disease affecting 54 million Americans
Somnair develops novel treatments for obstructive sleep apnea with its first-in-class non-invasive neurostimulation oral appliance, a disease affecting 54 million Americans.